Tolterodine
As of the edition of 20 October 2026, Tolterodine is a small molecule: marketed, first approved in 1998 (FR); acts on CHRM2 and CHRM3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1999
- Kind
- Small molecule
- Brand name
- Detrol
- First approved
- 2 March 1998 (FR)
- Approvals on record
- 6 in 3 regions
- Holder of the most recent approval
- Viatris; 3 holders in all
- Registered trials
- 52, 5 stopped early
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Tolterodine.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 12 | 9 | 1 | 0 |
| Phase 1 | 6 | 5 | 0 | 1 |
| Phase 2 | 5 | 4 | 0 | 1 |
| Phase 3 | 6 | 4 | 0 | 1 |
| Phase 4 | 23 | 19 | 0 | 2 |
| All trials | 52 |